Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Escape From ALL-CARTaz

1 May 2019

Abstract excerpt

Chimeric antigen receptor (CAR) T-cell therapy has been transformative for the treatment of B-cell malignancies, with CD19- and CD22-directed CARs being prime examples. However, immunoediting and ensuing antigen loss remain the major obstacles to curative therapy in up to 25% of patients. For example, to achieve the CD19-negative phenotype, malignant cells can pick from a broad array of mechanisms, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31135529
DOI: 10.1097/ppo.0000000000000381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Escape From ALL-CARTazPMID 31135529Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Tumor Antigen Escape from CAR T-cell TherapySemantic proximity Read ↗

Stalled CARs: Mechanisms of Resistance to CAR T Cell TherapiesSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

TCR activation impairs CAR-T cytotoxicity against separate target cellsSemantic proximity Read ↗

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionSemantic proximity Read ↗

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapySemantic proximity Read ↗

Engineering better chimeric antigen receptor T cellsSemantic proximity Read ↗

Impaired tumor death receptor signaling drives resistance to CAR T cell therapySemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

Multipurposing CARs: Same engine, different vehiclesSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.